T-MAXIMUM secures US FDA clearance for Phase 2 CAR-T trial
October 13, 2026 | 14:52
Biotechnology firm T-MAXIMUM received regulatory clearance from the US Food and Drug Administration to initiate a Phase 2 trial of MT027 for secondary brain metastases.
Mobile Version